Updates and Statements

12.21.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter

12.15.2023

Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment

11.13.2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

10.25.2023

Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

10.13.2023

Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma

10.05.2023

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

10.02.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter

09.25.2023

Pfizer’s Rocky Mount Facility Restarts Production Amid First Phase of Post-Tornado Recovery Efforts

09.07.2023

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07.21.2023

Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment

07.21.2023

Pfizer Receives Positive CHMP Opinion for RSV Vaccine Candidate to Help Protect Infants through Maternal Immunization and Older Adults

06.30.2023

Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics